Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) will be posting its quarterly earnings results after the market closes on Monday, November 6th. Analysts expect Tabula Rasa Healthcare to post earnings of $0.06 per share for the quarter.

Tabula Rasa Healthcare (NASDAQ:TRHC) last posted its earnings results on Monday, August 7th. The company reported $0.06 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.06. The company had revenue of $29.70 million for the quarter, compared to the consensus estimate of $27.84 million. Tabula Rasa Healthcare had a negative return on equity of 9.58% and a negative net margin of 10.27%. The firm’s revenue was up 32.6% on a year-over-year basis. On average, analysts expect Tabula Rasa Healthcare to post $0.07 EPS for the current fiscal year and $0.49 EPS for the next fiscal year.

Tabula Rasa Healthcare Inc. (TRHC) traded down 0.99% during mid-day trading on Monday, reaching $26.11. The company’s stock had a trading volume of 16,133 shares. Tabula Rasa Healthcare Inc. has a 52 week low of $10.39 and a 52 week high of $28.53. The firm’s market capitalization is $451.34 million. The firm’s 50 day moving average price is $26.18 and its 200 day moving average price is $26.18.

TRADEMARK VIOLATION NOTICE: “Tabula Rasa Healthcare Inc. (TRHC) to Release Earnings on Monday” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/30/tabula-rasa-healthcare-inc-trhc-to-release-earnings-on-monday.html.

In other news, CEO Calvin H. Knowlton sold 8,000 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $17.21, for a total value of $137,680.00. Following the completion of the sale, the chief executive officer now owns 918,362 shares of the company’s stock, valued at $15,805,010.02. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders sold 24,000 shares of company stock valued at $527,920. 45.80% of the stock is currently owned by insiders.

An institutional investor recently raised its position in Tabula Rasa Healthcare stock. State Street Corp lifted its holdings in Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) by 38.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 69,673 shares of the company’s stock after buying an additional 19,506 shares during the period. State Street Corp owned about 0.40% of Tabula Rasa Healthcare worth $1,051,000 as of its most recent SEC filing. Institutional investors own 27.94% of the company’s stock.

A number of brokerages recently issued reports on TRHC. Wells Fargo & Company lifted their target price on Tabula Rasa Healthcare from $21.00 to $27.00 and gave the stock a “market perform” rating in a report on Thursday, October 19th. Piper Jaffray Companies restated an “overweight” rating and issued a $20.00 target price (up from $19.00) on shares of Tabula Rasa Healthcare in a report on Wednesday, August 9th. Robert W. Baird lifted their target price on Tabula Rasa Healthcare from $17.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday, August 8th. ValuEngine upgraded Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Finally, Chardan Capital lifted their target price on Tabula Rasa Healthcare from $19.50 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, August 8th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $25.57.

Tabula Rasa Healthcare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.